IL316118A - Novel tumor-specific antigen-targeted therapy for myeloid disorders and acute leukemia - Google Patents

Novel tumor-specific antigen-targeted therapy for myeloid disorders and acute leukemia

Info

Publication number
IL316118A
IL316118A IL316118A IL31611824A IL316118A IL 316118 A IL316118 A IL 316118A IL 316118 A IL316118 A IL 316118A IL 31611824 A IL31611824 A IL 31611824A IL 316118 A IL316118 A IL 316118A
Authority
IL
Israel
Prior art keywords
treatment
specific antigens
tumor specific
acute leukemias
novel tumor
Prior art date
Application number
IL316118A
Other languages
English (en)
Hebrew (he)
Inventor
Martina Pigazzi
Alessandra Biffi
Original Assignee
Altheia Science S R L
Martina Pigazzi
Alessandra Biffi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altheia Science S R L, Martina Pigazzi, Alessandra Biffi filed Critical Altheia Science S R L
Publication of IL316118A publication Critical patent/IL316118A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/33—Antibodies; T-cell engagers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4224—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/11—Antigen recognition domain
    • A61K2239/13—Antibody-based
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
IL316118A 2022-04-05 2023-04-05 Novel tumor-specific antigen-targeted therapy for myeloid disorders and acute leukemia IL316118A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263327757P 2022-04-05 2022-04-05
US202263478068P 2022-12-30 2022-12-30
PCT/EP2023/059054 WO2023194501A1 (en) 2022-04-05 2023-04-05 Treatment of myeloid disorders and acute leukemias targeting novel tumor specific antigens

Publications (1)

Publication Number Publication Date
IL316118A true IL316118A (en) 2024-12-01

Family

ID=86226509

Family Applications (1)

Application Number Title Priority Date Filing Date
IL316118A IL316118A (en) 2022-04-05 2023-04-05 Novel tumor-specific antigen-targeted therapy for myeloid disorders and acute leukemia

Country Status (9)

Country Link
EP (1) EP4504784A1 (enExample)
JP (1) JP2025511758A (enExample)
KR (1) KR20250042204A (enExample)
CN (1) CN119317643A (enExample)
AU (1) AU2023250214A1 (enExample)
CA (1) CA3255414A1 (enExample)
IL (1) IL316118A (enExample)
MX (1) MX2024012390A (enExample)
WO (1) WO2023194501A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025113671A1 (zh) * 2023-12-01 2025-06-05 上海邦耀生物科技有限公司 Car、表达car的细胞及其用途
CN118440198B (zh) * 2024-04-03 2024-11-15 武汉爱博泰克生物科技有限公司 抗人cd69蛋白的兔单克隆抗体及其应用
CN120678778B (zh) * 2025-05-12 2026-01-27 山东康盛医疗器械股份有限公司 药物组合物在弥漫大b细胞淋巴瘤治疗中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US7750116B1 (en) 2006-02-18 2010-07-06 Seattle Genetics, Inc. Antibody drug conjugate metabolites
EP3964237B1 (en) 2013-03-15 2026-02-18 Regeneron Pharmaceuticals, Inc. Biologically active molecules, conjugates thereof, and therapeutic uses
DK3105317T3 (en) * 2014-02-14 2019-01-14 Cellectis Immunotherapy cells that are genetically engineered to target antigen on both immune cells and pathological cells
WO2018002902A1 (en) 2016-07-01 2018-01-04 Glaxosmithkline Intellectual Property (No.2) Limited Antibody-drug conjugates and therapeutic methods using the same
EP3793591A1 (en) * 2018-05-17 2021-03-24 Regeneron Pharmaceuticals, Inc. Anti-cd63 antibodies, conjugates, and uses thereof
US12534532B2 (en) * 2018-10-26 2026-01-27 Crage Medical Co., Limited CLL1-targeting antibody and application thereof
IL307498A (en) * 2021-04-05 2023-12-01 Altheia Science S R L Diagnosis and treatment of myeloid disorders and acute leukemia using antigens specific to new tumors

Also Published As

Publication number Publication date
CA3255414A1 (en) 2023-10-12
KR20250042204A (ko) 2025-03-26
AU2023250214A1 (en) 2024-11-21
EP4504784A1 (en) 2025-02-12
JP2025511758A (ja) 2025-04-16
MX2024012390A (es) 2025-01-09
CN119317643A (zh) 2025-01-14
WO2023194501A1 (en) 2023-10-12

Similar Documents

Publication Publication Date Title
IL280707B2 (en) Diagnostic and therapeutic methods for treating breast cancer
NZ709293A (en) Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
IL307498A (en) Diagnosis and treatment of myeloid disorders and acute leukemia using antigens specific to new tumors
ES3066432T3 (en) New therapeutic combinations comprising pirfenidone and pde4-inhibitor for the treatment of progressive fibrosing interstitial lung diseases
IL326404A (en) Fused pyridines for the treatment of cancer and other indications
AU201814591S (en) Ultrasound therapeutic treatment transducer
SG11202100947SA (en) Treatment of metastatic brain tumor by administration of antibody-drug conjugate
WO2019103998A3 (en) Promoting trained immunity with therapeutic nanobiologic compositions
IL325828A (en) Novel compounds for the treatment of cancer and metabolic diseases
AU2021381324A9 (en) Methods of treating diseases and disorders
IL314195A (en) Cancer treatment targeting DLL3
EP4090420A4 (en) PHOTOTHERAPEUTIC TREATMENT OF SKIN DISEASES
IL313491A (en) Managbodies directed to P53 tumor antigens and methods of use
EP4170035A4 (en) APPLICATION OF METHIONASE GENE THERAPY IN THE TREATMENT OF MALIGNANT TUMORS
PT4153232T (pt) Terapêutica com imunoconjugado de tnf-a para o tratamento de tumores cerebrais
MX2025011869A (es) Terapia de combinacion que comprende un inhibidor de parg y un inhibidor de topoisomerasa para tratar cancer
EP4355355A4 (en) TREATMENT OF PLIN1-ASSOCIATED DISEASES AND DISORDERS
HK40115445A (en) Treatment of myeloid disorders and acute leukemias targeting novel tumor specific antigens
IL318791A (en) Pyridopyrazoles as DDR'S inhibitors for the treatment of lipid disorders and cancer
IL315443A (en) Combined gene and radiation therapy for cancer treatment
HK40108526A (en) Diagnosis and treatment of myeloid disorders and acute leukemias using novel tumor specific antigens
WO2008098183A3 (en) Combination therapy for treating cancer
EP4157246B8 (en) Therapeutic combination for the treatment of breast cancer
IL326327A (en) Treatment of prostate cancer
MX393477B (es) Combinación de vorasidenib con radiación y/o agentes adicionales para tratar gliomas.